---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-001439"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:52:43.071062+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q4 2024 net revenue $201.3M, FY $714.7M; guides 2025 $820-860M

## Summary
- Q4 2024 net product revenue $201.3M (+20% YoY); FY 2024 net revenue $714.7M (+23% YoY).
- Q4 GAAP net income $49.5M ($0.85 diluted EPS); non-GAAP adjusted net income $63.0M ($1.08 diluted EPS).
- 2025 WAKIX net revenue guidance set at $820M-$860M; on track for potential $1B+ narcolepsy opportunity.
- Phase 3 topline for ZYN002 in Fragile X syndrome expected Q3 2025; pitolisant HD trials to start Q4 2025.
- Settled first ANDA litigation with Novugen; generic license begins Jan 2030 or earlier under certain conditions.

## SEC filing metadata
- accession: 0001558370-25-001439
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/0001558370-25-001439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837025001439/hrmy-20250225x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-001439
- JSON: https://secwatch.observer/filing/0001558370-25-001439.json
- Plain text: https://secwatch.observer/filing/0001558370-25-001439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.